Topic:

R&D

Latest Headlines

Latest Headlines

Pfizer's cooking up a PCSK9-blocking pill

SAN FRANCISCO-- Keeping up the rear in a three-way race to commercialize the first of a new class of anticholesterol antibodies, Pfizer is at work on a pill that attacks the same target, planning to build a franchise in what is expected to be a blockbuster new therapeutic area.

Lilly cuts in on immuno-oncology with Merck, Bristol-Myers

Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.

Veterans say experimental, 'brain zapping' magnetic resonance therapy can treat PTSD

Veterans interviewed by the Washington Post hail experimental magnetic resonance therapy as a possible treatment for post-traumatic stress disorder. Families of autistic children made similar claims.

J&J takes another leap into microbiome R&D with $241M Vedanta pact

J&J subsidiary Janssen Biotech has inked a deal to collaborate with Boston-based Vedanta on a new bacterial treatment for inflammatory bowel disease, or IBD. And it handed over an undisclosed upfront payment and promises of up to $241 million in milestones if their partnership can blaze a path to the market eventually.

Alnylam and Isis strengthen RNAi alliance, agree to swap IP

Alnylam and Isis Pharmaceuticals announced an intellectual property cross-licensing agreement that they hope will leave them both better equipped to deal with the challenges of developing the first commercial RNAi therapy, including utilization of the promising but still-unproven RNA interference drug delivery pathway, and sometimes jittery investors.

Mersana lines up for $300M in an R&D deal with Takeda

Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.

JP Morgan: Oracle to use Proteus' 'digital pills' in its clinical trial management platform

Oracle announced that it will deploy Proteus' digital pill into its clinical trial data capture and management solution to track patient adherence to dosing instructions during trials, and provide insights into drug efficacy and safety. The development at the gargantuan JP Morgan Healthcare Conference in San Francisco is another win for ingestible devices, as well as Proteus, the recipient of a $172 million Series G financing in July last year.

Evotec extends a biotech deal with $13M on the line

Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.

PPD's in-house biotech pairs up with J&J

X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.

23andMe strikes $60M Genentech deal to continue pivot to database-driven R&D

Genentech has given 23andMe a major boost. The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease.